Arbutus Biopharma Corp

ABUS

$5.12

+0.39%

N/A+$0.02

Healthcare

Biotechnology

NASDAQ

Active Trading

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus ...

Fundamental Analysis of ABUS

Key Strengths

Strong focus on functional cure for chronic HBV, addressing a significant unmet medical need.

Proprietary LNP delivery technology with licensing agreements (e.g., Alnylam, Gritstone) generating non-dilutive revenue.

Risk Factors

Clinical-stage company with no approved products; high risk of trial failures or delays.

Negative cash flow from operations, requiring future capital raises, which may dilute shareholders.

Profitability

Net Margin84.23%

Operating Margin81.01%

Valuation

P/E Ratio6.48x

Current Ratio81.42

Efficiency

ROE90.98%

ROA55.85%

Fundamental Analysis of ABUS

Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing a cure for chronic Hepatitis B virus (HBV) infection. The company's lead candidate, imdusiran (AB-729), is an RNAi therapeutic designed to suppress all HBV antigens, including HBsAg, and is currently in Phase 2a trials. Additionally, the company is developing AB-101, an oral PD-L1 inhibitor, in Phase 1a/1b trials to reawaken the immune response against HBV. Arbutus also holds licensing agreements for its lipid nanoparticle (LNP) delivery technology, notably with Alnylam Pharmaceuticals, which provides a source of non-dilutive revenue and validates its platform. The company has a strong balance sheet with no debt, a current ratio of 54.3, and cash reserves supporting operations. However, as a clinical-stage company, Arbutus generates minimal revenue and is not profitable, with negative operating cash flow and free cash flow. The stock trades at a low price-to-earnings ratio (5.55) due to accounting gains, but this is not indicative of underlying profitability. The company's market capitalization is approximately $915 million, and its enterprise value is about $895 million. Recent developments include a licensing deal with Gritstone Oncology, providing upfront and milestone payments. Analyst sentiment is mixed, with a consensus rating of 'Hold' and a price target around $5.00, reflecting both the potential of the HBV pipeline and the risks inherent in clinical development. The long-term outlook is uncertain but promising, contingent on successful clinical trial outcomes and regulatory approvals.

Key Strengths of ABUS

Strong focus on functional cure for chronic HBV, addressing a significant unmet medical need.
Proprietary LNP delivery technology with licensing agreements (e.g., Alnylam, Gritstone) generating non-dilutive revenue.
Robust balance sheet with no debt and high cash reserves (current ratio >50).
Experienced management team with proven track record in virology and drug development.
Multiple pipeline candidates targeting different mechanisms (RNAi, immunomodulation) to potentially combine for a cure.
Large market opportunity; chronic HBV affects over 250 million people worldwide.

Risk Factors of ABUS

Clinical-stage company with no approved products; high risk of trial failures or delays.
Negative cash flow from operations, requiring future capital raises, which may dilute shareholders.
Dependence on partnership revenues; if licensing deals underperform, revenue may be insufficient.
Intense competition from other HBV therapies, including from GSK, Gilead, and other biotechs.
Regulatory and manufacturing risks associated with novel therapies.
Limited analyst coverage and volatile stock price due to binary clinical outcomes.
Potential intellectual property disputes over LNP technology.

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$1.01B

6.5x

P/E Ratio

5.6x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin99.98%

Net Profit Margin84.23%

Debt/Equity Ratio0.01

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of ABUS

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of ABUS

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	-507.20%	—	—	Flat
Operating Margin	—	-588.17%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of ABUS

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	81.416	—	—	Flat
Quick Ratio	—	81.416	—	—	Flat
Debt / Equity	—	0.014	—	—	Flat

Valuation of ABUS

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-40.00x	—	—	Flat
P/B	—	3.66x	—	—	Flat

Supply Chain of ABUS

RELATIONS

Upstream

Genevant Sciences Ltd.Third-Party CDMOs (Drug Substance & Drug Product Manufacturing)X-Chem Inc.Proteros biostructures GmbHLipid Excipient Manufacturers (CordenPharma, Merck KGaA, etc.)Oligonucleotide Raw Material Suppliers

Downstream

Moderna, Inc.NASDAQ:MRNA Alnylam Pharmaceuticals, Inc.NASDAQ:ALNY Barinthus Biotherapeutics plcNASDAQ:BRNS Roivant Sciences Ltd.NASDAQ:ROIVAcuitas Therapeutics Inc.Qilu Pharmaceutical Co., Ltd.Gritstone bio, Inc. (fka Gritstone Oncology)

Proxies

Alnylam Pharmaceuticals, Inc.NASDAQ:ALNY Moderna, Inc.NASDAQ:MRNA Roivant Sciences Ltd.NASDAQ:ROIV Barinthus Biotherapeutics plcNASDAQ:BRNS Gilead Sciences, Inc.NASDAQ:GILD

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer